KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Change in Accured Expenses (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Change in Accured Expenses data on record, last reported at -$2.6 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 90.0% year-over-year to -$2.6 million; the TTM value through Dec 2025 reached $79.3 million, up 387.31%, while the annual FY2025 figure was $79.3 million, 387.31% up from the prior year.
  • Change in Accured Expenses reached -$2.6 million in Q4 2025 per CRL's latest filing, down from $42.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $51.3 million in Q2 2021 and bottomed at -$79.8 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $3.3 million, with a median of $4.9 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: surged 563.47% in 2023, then plummeted 188.33% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $26.1 million in 2021, then crashed by 136.14% to -$9.4 million in 2022, then crashed by 69.58% to -$16.0 million in 2023, then tumbled by 60.23% to -$25.6 million in 2024, then surged by 90.0% to -$2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$2.6 million in Q4 2025, $42.9 million in Q3 2025, and $23.7 million in Q2 2025.